By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Asuragen said today that Biomedical Diagnostics (BMD) will distribute its cancer assays in France.

The agreement covers Asuragen's Signature Oncology Portfolio, a line of multiplex assays used to detect mutations in solid and hematologic malignancies. The tests use RT-PCR and multiplex detection using the Luminex 100 or 200 systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.